S.NO. |
Age
in years |
Cases |
Percentage |
1 2 3 4 5 6 |
0-20 21-30 31-40 41-50 51-60 Above
60 |
1 7 13 12 5 2 |
2.5% 17.5% 32.5% 30.0% 12.5% 5.0% |
|
Total |
40 |
100.0% |
S.
No |
Type |
Male |
Percentage |
Female |
Percentage |
1. |
I |
12 |
30.0% |
23 |
57.5% |
2. |
II |
NIL |
NIL |
2 |
5.0% |
3. |
III |
NIL |
NIL |
3 |
7.5% |
Total |
12 |
30.0% |
28 |
70.0% |
S.NO |
Organism |
Cases |
Percentage |
1. |
Staphylococccus |
8 |
20.0% |
2. |
Streptococcus |
5 |
12.5% |
3. |
Pneumococcus |
5 |
12.5% |
4. |
Sterile |
22 |
55.0% |
|
Total |
40 |
100.0% |
S.NO |
Changes |
Cases |
Percentage |
1. |
Hypertrophy |
31 |
77.5% |
2. |
Denudation |
15 |
37.5% |
3. |
Metaplasia |
23 |
57.5% |
4. |
Goblet
cell formation |
22 |
55.0% |
5. |
Papillae
formation |
9 |
22.5% |
R |
S |
Total |
%
S |
%
R |
|
Amoxycillin-
Clavulanic acid |
4 |
14 |
18 |
78 |
22 |
Amikacin |
1 |
8 |
9 |
89 |
11 |
Cefepime |
3 |
15 |
18 |
83 |
17 |
Cefotaxime |
3 |
15 |
18 |
83 |
17 |
Ceftazidime |
3 |
15 |
18 |
83 |
17 |
Ceftriaxone |
3 |
15 |
18 |
83 |
17 |
Cefuroxime |
3 |
15 |
18 |
83 |
17 |
Ciprofloxacin |
9 |
8 |
17 |
47 |
53 |
Clindamycin |
5 |
12 |
17 |
71 |
29 |
Co-trimoxazole |
9 |
8 |
17 |
47 |
53 |
Erythromycin |
12 |
4 |
16 |
25 |
75 |
Gentamicin |
6 |
12 |
18 |
67 |
33 |
Imipenem |
3 |
15 |
18 |
83 |
17 |
Penicillin
G |
13 |
5 |
18 |
28 |
72 |
Piperacillin-
Tazobactam |
3 |
15 |
18 |
83 |
17 |
Vancomycin |
0 |
16 |
16 |
100 |
0 |